Dolutegravir-associated resistance mutations after first-line treatment failure in Brazil
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Dolutegravir-associated resistance mutations after first-line treatment failure in Brazil ; volume:23 ; number:1 ; day:24 ; month:5 ; year:2023 ; pages:1-10 ; date:12.2023
BMC infectious diseases ; 23, Heft 1 (24.5.2023), 1-10, 12.2023
- Creator
-
Diaz, Ricardo Sobhie
Hunter, James R.
Camargo, Michelle
Dias, Danilo
Galinskas, Juliana
Nassar, Isabela
Lima, Isaac Barbosa de
Caldeira, Debora Bellini
Sucupira, Maria Cecilia
Schechter, Mauro
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12879-023-08288-8
- URN
-
urn:nbn:de:101:1-2023091012585693644731
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:51 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Diaz, Ricardo Sobhie
- Hunter, James R.
- Camargo, Michelle
- Dias, Danilo
- Galinskas, Juliana
- Nassar, Isabela
- Lima, Isaac Barbosa de
- Caldeira, Debora Bellini
- Sucupira, Maria Cecilia
- Schechter, Mauro
- SpringerLink (Online service)
Other Objects (12)
Probing Resistance Mutations in Retroviral Integrases by Direct Measurement of Dolutegravir Fluorescence
Patterns of drug resistance mutations after failure of first-line NNRTI-based antiretroviral therapy in Western India
GBA mutations and Parkinson's disease in Brazil
PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer
Dolutegravir: Nutzenbewertung gemäß § 35a SGB V
Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations
High rates of transmitted NNRTI resistance among persons with acute HIV infection in Malawi: implications for first-line dolutegravir scale-up
Cost-Utility Analysis of Dolutegravir- Versus Efavirenz-Based Regimens as a First-Line Treatment in Adult HIV/AIDS Patients in Ethiopia
Knowledge and perceptions about Dolutegravir and Dolutegravir counselling: a qualitative study among women living with HIV
Creation of a long-acting nanoformulated dolutegravir
Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? a case report
Modifying dolutegravir to PrEPare for long life
Probing Resistance Mutations in Retroviral Integrases by Direct Measurement of Dolutegravir Fluorescence
Patterns of drug resistance mutations after failure of first-line NNRTI-based antiretroviral therapy in Western India
GBA mutations and Parkinson's disease in Brazil
PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer
Dolutegravir: Nutzenbewertung gemäß § 35a SGB V
Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations
High rates of transmitted NNRTI resistance among persons with acute HIV infection in Malawi: implications for first-line dolutegravir scale-up
Cost-Utility Analysis of Dolutegravir- Versus Efavirenz-Based Regimens as a First-Line Treatment in Adult HIV/AIDS Patients in Ethiopia
Knowledge and perceptions about Dolutegravir and Dolutegravir counselling: a qualitative study among women living with HIV
Creation of a long-acting nanoformulated dolutegravir
Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? a case report
Modifying dolutegravir to PrEPare for long life
Probing Resistance Mutations in Retroviral Integrases by Direct Measurement of Dolutegravir Fluorescence
Patterns of drug resistance mutations after failure of first-line NNRTI-based antiretroviral therapy in Western India
GBA mutations and Parkinson's disease in Brazil
PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer
Dolutegravir: Nutzenbewertung gemäß § 35a SGB V
Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations
High rates of transmitted NNRTI resistance among persons with acute HIV infection in Malawi: implications for first-line dolutegravir scale-up
Cost-Utility Analysis of Dolutegravir- Versus Efavirenz-Based Regimens as a First-Line Treatment in Adult HIV/AIDS Patients in Ethiopia
Knowledge and perceptions about Dolutegravir and Dolutegravir counselling: a qualitative study among women living with HIV
Creation of a long-acting nanoformulated dolutegravir
Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? a case report